Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-10-04
2010-11-30
Mondesi, Robert B (Department: 1645)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07842474
ABSTRACT:
Ehrlichia canisantigens that can be used to differentiateE. canisinfected animals from animals that have been challenged withE. canis, e.g., vaccinated againstE. canis, are disclosed. The invention also provides compositions and methods for determining the presence ofE. canisantigens and antibodies.
REFERENCES:
patent: 4894576 (1990-01-01), Okamoto et al.
patent: 5726010 (1998-03-01), Clark
patent: 6043085 (2000-03-01), Yu et al.
patent: 6355777 (2002-03-01), Walker et al.
patent: 6392023 (2002-05-01), Walker et al.
patent: 6403780 (2002-06-01), Walker et al.
patent: 6458942 (2002-10-01), Walker et al.
patent: 6660269 (2003-12-01), Walker et al.
patent: 2002/0115840 (2002-08-01), Walker et al.
patent: 2003/0073095 (2003-04-01), Walker et al.
patent: 2003/0092087 (2003-05-01), Walker et al.
patent: 2003/0096250 (2003-05-01), Walker et al.
patent: 2003/0185849 (2003-10-01), Walker et al.
patent: 2004/0121433 (2004-06-01), McBride et al.
patent: 2004/0170972 (2004-09-01), Chang
patent: 2004/0198951 (2004-10-01), Walker et al.
patent: 2004/0247616 (2004-12-01), Walker et al.
patent: 2005/0260621 (2005-11-01), McBride et al.
patent: 2006/0211062 (2006-09-01), O'Connor, Jr.
patent: 2006/0234322 (2006-10-01), Krah et al.
patent: 2007/0003570 (2007-01-01), Murtaugh et al.
patent: 2009/0004217 (2009-01-01), Krah et al.
patent: WO 98/42743 (1998-10-01), None
patent: WO 00/12688 (2000-03-01), None
patent: WO 01/82862 (2001-11-01), None
patent: WO 03/089571 (2003-10-01), None
patent: WO 2004/042037 (2004-05-01), None
patent: WO 2006/107924 (2006-10-01), None
patent: WO 2006107924 (2006-10-01), None
patent: WO 2006/138509 (2006-12-01), None
patent: WO 2008/112007 (2008-09-01), None
Waner et al., Vet. Parasitol., 95:1-15, 2001.
McBride et al., J. Clin. Micriobiol., 39:315-322, 2001.
Yu et al. (J. Clin. Microbiol., 38:369-374, 2000.
Waner, et al., “Significance of serological testing for ehrlichial diseases in dogs with special emphasis on the diagnosis of canine moncytic ehrlichiosis caused byEhrlichia canis”, Veterinary Parasitology 95 (2001) 1-15.
Cardenas, et al., “Enzyme-Linked Immunosorbent Assay with Conserved Immunoreactive Glycoproteins gp36 and gp19 has Enhanced Sensitivity and Provides Species-Specific Immunodiagnosis ofEhrlichia canisInfection”, Clinical and Vaccine Immunology, vol. 14, No. 2, p. 123-128 (2007).
McBride, et al., “Kinetics of Antibody Response toEhrlichia canisImmunoreactive Proteins”, Infection and Immunity, vol. 71, No. 5, p. 2516-2524 (2003).
McBride, “Novel Immunoreactive glycoprotein orthologs ofEhrlichiaspp.”, Ann. NY Aca. Sci., 990:678-84, 2003—Abstract Only.
Office Action issued in correspondence U.S. Appl. No. 11/397,222 dated Jul. 18, 2008.
International Search Report and Written Opinion dated Feb. 2, 2007 for corresponding PCT application No. PCT/US2006/012432.
Yu, et al., “Molecular Cloning and Characterization of the 120-Kilodalton Protein Gene ofEhrlichia canisand Application of the Recombinant 120-Kilodalton Protein for Serodiagnosis of Canine Ehrlichiosis”, Journal of Clinical Microbiology, vol. 38, No. 1, p. 369-374 (2000).
McBride, et al., “Immunodiagnosis ofEhrlichia canisInfection with Recombinant Proteins”, Journal of Clinical Microbiology, vol. 39, No. 1, p. 315-322 (2001).
Mavromatis, et al., “The Genome of the Obligately Intracellular BacteriumEhrlichia canisReveals Themes of Complex Membrane Structure and Immune Evasion Strategies”, Journal of Bacteriology, vol. 188, No. 11, p. 4015-4023 (2006).
Office action corresponding to U.S. Appl. No. 11/397,222 (U.S. Publ. No. 20060234322) dated Feb. 23, 2009.
International Search Report and Written Opinion dated May 14, 2008 for corresponding PCT application No. PCT/US2007/080373.
Office Action issued in corresponding U.S. Appl. No. 11/397,222 dated Nov. 19, 2007.
Breitschwerdt, et al., “Doxycycline Hyclate Treatement of Experimental Canine Ehrlichiosis Followed by Challenge Inoculation with TwoEhrliichia canisStrains”, Antimicrobial Agents and Chemotherapy, vol. 42, No. 2, p. 362-368, 1998.
Yu, et al., “Comparison ofEhrlichia chaffeensisRecombinant Proteins for Serologic Diagnosis of Human Monocytotropic Ehrlichiosis”, Journal of Clinical Microbiology, vol. 37, No. 8, p. 2568-2575, 1999.
Yu, et al., “Molecular Cloning and characterization of the 120-Kilodalton Protein Gene ofEhrlichia canisand Application of the Recombinant 120-Kilodalton Protein for Serodiagnosis of Canine Ehrlichiosis”, Journal of Clinical Microbiology, vol. 38, No. 1, p. 369-374, 2000.
Accession No. NZ13AAEJ01000001 dated Oct. 4, 2004 (first page only).
Accession No. ZP—00211244 dated Oct. 4, 2004.
Accession No. ZP—00211130 dated Oct. 4, 2004.
Accession No. AAE96254 dated Apr. 20, 2002.
Accession No. ZP—00210575 dated Oct. 4, 2004.
Accession No. AAK01145 dated Oct. 6, 2003.
Accession No. AF252298 dated Oct. 6, 2003.
Accession No. AAD34330 dated Jan. 13, 2000.
Accession No. AF112369 dated Jan. 13, 2000.
Accession No. ZP—00211146 dated Oct. 4, 2004.
Database, “Major outer membrane protein p19”, Uniprot, Sep. 27, 2005. Retrieved from EBI Accession No. UNIPROT:Q3YSZ1, Database accession No. Q3YSZ1.
Mavromatis, et al., “The genome of the obligately intracellular bacteriumEhrlichia canisreveals themes of complex membrane structure and immune evasion strategies”, J. Bacteriol. 2006; 88(11):4015-23.
McBride, et al., “Identification of a glycosylatedEhrlichia canis19-kilodalton major immunoreactive protein with a species-specific serine-rich glycopeptide epitope”, Infect. Immuno. 2007; 75(1):74-82.
McBride, et al., “Molecular cloning of the gene for a conserved major immunoreactive 28-kilodalton protein ofEhrlichia canis: a potential serodiagnostic antigen”, Clin. Diagn. Lab. Immunol. 1999; 6(3):392-9.
Ndip, et al., “Ehrlichial Infection in Cameroonian canines byEhrlichia canisandEhrlichia ewingii”, Vet. Microbiol. 2005; 111(1-2):59-66.
Office action dated Oct. 15, 2009, for U.S. Appl. No. 11/397,222 (US 2006-0234322).
Greenspan et al., “Defining epitopes: It's not as easy as it seems”, Nature Biotechnology, vol. 17, pp. 936-937 (1999).
Holmes, “PSMA specific antibodies and their diagnostic and therapeutic use”, Exp. Opin. Invest. Drugs, 10(3), pp. 511-519 (2001).
Houghten et al., “Relative Importance of Position and Individual Amino Acid Residues in Peptide Antigen-Antibody Interactions: Implications in the Mechanism of Antigenic Drift and Antigenic Shift”, Vaccines 86, eds. Brown et al., Cold Spring Harbor Laboratory Press, pp. 21-25 (1986).
Office Action dated Apr. 1, 2010, for corresponding U.S. Appl. No. 12/262,709.
Gauither et al., “Western immunoblot analysis for distinguishing vaccination and infection status withBorrelia burgdorferi(Lyme disease) in dogs”, J. Vet. Diagn. Invest., 11:259-265 (1999).
Office Action dated Apr. 14, 2010 for U.S. Appl. No. 11/397,222.
Beall Melissa
Krah, III Eugene Regis
O'Connor, Jr. Thomas Patrick
Gangle Brian J
IDEXX Laboratories, Inc.
McDonnell Boehnen & Hulbert & Berghoff LLP
Mondesi Robert B
LandOfFree
Ehrlichia canis DIVA (differentiate infected from... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ehrlichia canis DIVA (differentiate infected from..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ehrlichia canis DIVA (differentiate infected from... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4223952